REED JAN STERN 4
4 · AVITA Medical, Inc. · Filed Jun 4, 2026
Research Summary
AI-generated summary of this filing
AVITA Medical Director Reed Jan Stern Receives RSUs and Options
What Happened Reed Jan Stern, a director of AVITA Medical, received two equity awards with a grant date of January 20, 2026: 22,214 restricted stock units (RSUs) and an option grant covering 16,133 shares. The option exercise price is $3.77 per share (Nasdaq closing price on the grant date). Both awards were subject to and received stockholder approval on June 3, 2026. These are compensation awards (not open‑market purchases or sales).
Key Details
- Transaction dates: Grant date January 20, 2026; stockholder approval obtained June 3, 2026; Form 4 filed June 4, 2026.
- RSUs: 22,214 RSUs awarded; RSUs vest 12 months after the grant date (per footnote). Includes unvested RSUs.
- Options: 16,133 stock options granted with an exercise price of $3.77 per share (grant described as a derivative award).
- Cash reported: RSU award reflected as an acquisition (no cash paid); option grant reported with $0 cash outlay on grant (typical for option awards).
- Shares owned after transaction: not specified in the filing.
- Timeliness: Filing was submitted the day after stockholder approval and appears timely (not marked late).
Context RSUs are a deferred-share award that convert into common stock upon vesting (here, 12 months after the grant). Stock options give the holder the right to buy shares at the stated strike ($3.77) — they are not exercised by this filing. Grants to non-executive directors are commonly part of routine compensation and do not by themselves indicate immediate buying or selling sentiment.
Insider Transaction Report
- Award
Common Stock
[F1][F2]2026-01-20+22,214→ 73,225 total - Award
Stock Options (Right to Buy)
[F3]2026-01-20+16,133→ 16,133 totalExercise: $3.77From: 2027-01-20Exp: 2036-01-20→ Common Stock (16,133 underlying)
Footnotes (3)
- [F1]Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
- [F2]Includes unvested RSUs.
- [F3]On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.